title: Treatment with DPP-4 inhibitors does not increase the chance of pancreatitis in patients with type 2 diabetes.
abstract: OBJECTIVE
  This retrospective analysis was done in type 2 diabetes patients to study whether treatment with either sitagliptin or other Dipeptidyl peptidase-4 (DPP-4) inhibitors increased the risk of pancreatitis. Comparison with patients treated with other Oral Antidiabetic Drugs (OADs) was done.
  
  
  METHODS
  Asian Indian type 2 diabetic subjects (duration > or = 5 years) treated with sitagliptin or other DPP-4 inhibitors (n = 957) were selected from the clinic records. Control group included patients treated with other hypoglycaemic agents and had serum lipase and/or amylase estimated (n = 718). HbA1c and serum levels of lipase and/or amylase were measured. For lipase, values > or = 90 IU/l and for amylase, values > or = 150 IU/l were considered abnormal.
  
  
  RESULTS
  Percentages with elevated lipase values were similar among patients on sitagliptin or other gliptins and control subjects. Similar percentages of patients using DPP-4 inhibitors (6.9%) or other hypoglycaemic agents (8.2%) had elevated levels of lipase. Abnormal amylase values were more common among the control subjects vs those using DPP-4 inhibitors.
  
  
  CONCLUSIONS
  Present analysis suggests that use of DPP-4 inhibitors is safe in patients who do not have contraindications for its use.
authors.forename: Ananth Samith
authors.initials: AS
authors.lastname: Shetty
authors.forename: Arun
authors.initials: A
authors.lastname: Nandith
authors.forename: Chamukuttan
authors.initials: C
authors.lastname: Snehalath
authors.forename: Ambady
authors.initials: A
authors.lastname: Ramachandran
mesh_terms: D000328:Adult; D000368:Aged; D000681:Amylases / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D008049:Lipase / Q000097:blood; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000139:chemically induced*; D011719:Pyrazines / Q000009:adverse effects*; D012189:Retrospective Studies; D018570:Risk Assessment; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000009:adverse effects*
chemical_list: D000681:Amylases; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008049:Lipase; D011719:Pyrazines; D000068900:Sitagliptin Phosphate; D014230:Triazoles; C517652:hemoglobin A1c protein, human